These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 12173280)

  • 1. The hidden costs of arthritis treatment and the cost of new therapy--the burden of non-steroidal anti-inflammatory drug gastropathy.
    Moore RA
    Rheumatology (Oxford); 2002 Apr; 41 Supp 1():7-15; discussion 35-42. PubMed ID: 12173280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs.
    Laine L; Wogen J; Yu H
    Gastroenterology; 2003 Aug; 125(2):389-95. PubMed ID: 12891540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
    Chancellor JV; Hunsche E; de Cruz E; Sarasin FP
    Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy.
    Fendrick AM
    Cleve Clin J Med; 2002; 69 Suppl 1():SI59-64. PubMed ID: 12086296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
    Hur C; Chan AT; Tramontano AC; Gazelle GS
    Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
    Moore A; Phillips C; Hunsche E; Pellissier J; Crespi S
    Pharmacoeconomics; 2004; 22(10):643-60. PubMed ID: 15244490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effective use of NSAIDs: issues pertinent to coxib use in managed care.
    Fendrick AM
    Am J Manag Care; 2002 Nov; 8(17 Suppl):S529-41. PubMed ID: 12458822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology and pharmacoeconomic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity.
    MacDonald TM
    Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():13-20; discussion 57-9. PubMed ID: 11276797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
    Tannenbaum H; Bombardier C; Davis P; Russell AS;
    J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
    Spiegel BM; Chiou CF; Ofman JJ
    Arthritis Rheum; 2005 Apr; 53(2):185-97. PubMed ID: 15818647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment costs to prevent or treat upper gastrointestinal adverse events associated with NSAIDs.
    Rahme E; Barkun AN; Adam V; Bardou M
    Drug Saf; 2004; 27(13):1019-42. PubMed ID: 15471508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
    ;
    Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):81-85. PubMed ID: 28056333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis.
    Burke TA; Zabinski RA; Pettitt D; Maniadakis N; Maurath CJ; Goldstein JL
    Pharmacoeconomics; 2001; 19 Suppl 1():33-47. PubMed ID: 11280104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal effects of NSAIDs and coxibs.
    Laine L
    J Pain Symptom Manage; 2003 Feb; 25(2 Suppl):S32-40. PubMed ID: 12604155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomic modeling of prior-authorization intervention for COX-2 specific inhibitors in a 3-tier copay plan.
    Stacy J; Shaw E; Arledge MD; Howell-Smith D
    J Manag Care Pharm; 2003; 9(4):327-34. PubMed ID: 14613451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib.
    Steinfeld S; Bjørke PA
    Rheumatology (Oxford); 2002 Apr; 41 Supp 1():23-7; discussion 35-42. PubMed ID: 12173277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gastrointestinal side effects of non-steroidal anti-inflammatory drugs in high-risk patients--role of selective cyclooxygenase inhibitors].
    Prónai L
    Orv Hetil; 2001 Sep; 142(35):1899-905. PubMed ID: 11601177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is no NSAID a good NSAID? Approaches to NSAID-associated upper gastrointestinal disease.
    Chang SY; Howden CW
    Curr Gastroenterol Rep; 2004 Dec; 6(6):447-53. PubMed ID: 15527674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
    Joshua FF; Oakley SP; Major GA
    Intern Med J; 2004 Apr; 34(4):153-61. PubMed ID: 15086694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One hundred years of NSAID gastropathy: are coxibs the answer?
    Bjorkman DJ
    Rev Gastroenterol Disord; 2001; 1(3):121-7. PubMed ID: 12120179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.